Abstract

BackgroundAll of the components of Metabolic syndrome (MetS) have been regarded as risk factors for coronary artery disease (CAD). Early detection of CAD in asymptomatic patients with MetS remains a challenge. Cystatin C,which has been proposed as a novel marker of renal dysfunction,is correlated with mortality in CAD, The purpose of the study was to evaluate whether cystatin C is a potential marker of asymptomatic CAD in MetS patients with normal kidney function.MethodsA total of 211asymptomatic MetS patients without prior history of CAD patients were included in a cross-sectional study. Patients were divided into MetS with asymptomatic CAD (n = 136) and MetS without CAD (n = 75) groups according to coronary angiograph results. Serum cystatin C levels were measured using particle enhanced immunonephelometric assays. We first assessed whether there is an independent association of cystatin C with the presence and severity of asymptomatic CAD. Then, we investigated the association between cystatin C and other biochemical risk factors for atherosclerosis.ResultsSerum cystatin C levels in patients with asymptomatic CAD were significantly higher than those without CAD (P = 0.004). A multiple logistic regression analysis demonstrated cystatin C was independently associated with the presence of asymptomatic CAD (OR = 1.326, 95%CI: 1.086-1.619). On receiver operating characteristics (ROC) analysis, the area under the curve (AUC) was 0.622 (95 % CI: 0543–0.701, P = 0.003), and cystatin C showed a moderate predictive value. Furthermore, cystatin C was independently correlated with Gensini score (standardized β = 0.183, P = 0.007), and serum cystatin C levels increased with the increasing of number of disease vessels (P = 0.005). In a multiple stepwise regression analysis, uric acid (UA)(P < 0.001), body mass index (BMI)(P = 0.002), triglyceride(TG)(P = 0.03), estimated glomerular filtration rate (eGFR)(P < 0.001), and fibrinogen(P = 0.001) were independently associated with cystatin C.ConclusionsSerum cystatin C in our study was significantly associated with the presence and severity of asymptomatic CAD in MetS patients with normal kidney function, suggesting that cystatin C is probably more than a marker of glomerular filtration rate.

Highlights

  • All of the components of Metabolic syndrome (MetS) have been regarded as risk factors for coronary artery disease (CAD)

  • Individuals with angina pectoris or anginal-equivalent symptoms suggestive of CAD, valvular heart disease, malignancy, inflammatory disease, renal dysfunction, hepatic dysfunction were excluded from the study

  • Serum cystatin C (odds ratio, OR = 1.326, 95% confidence interval(CI):1.086-1.619, P = 0.006), fibrinogen (OR = 1.629, 95% CI: 1.043-2.543, P = 0.032), fasting plasma glucose (FPG) (OR = 1.363, 95% CI: 1.088-1.707, P = 0.007) and smoking (OR = 1.913, 95% CI: 1.007-3.633, P = 0.048) were independent predictors of the presence of the asymptomatic CAD

Read more

Summary

Introduction

All of the components of Metabolic syndrome (MetS) have been regarded as risk factors for coronary artery disease (CAD). Detection of CAD in asymptomatic patients with MetS remains a challenge. Each of the components have been recognized as risk factors for coronary artery disease (CAD)[2], and today a series of previous studies have demonstrated that the presence of MetS is associated with an increased risk of developing CAD [3,4]. Asymptomatic patients have a higher cardiac mortality risk than those with symptomatic CAD [5]. An early identification and treatment of asymptomatic CAD patients may significantly improve their cardiovascular prognosis. The early diagnosis of asymptomatic CAD is always missed or delayed because the typical symptoms of cardiac ischemia are often masked. Classic assessment such as Framingham Risk Score (FRS) could not identify asymptomatic CAD effectively. Biochemical markers might play crucial roles on initial assessment of asymptomatic CAD

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call